Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16

Yi,Ja  Woon; Jang,Mi; Kim,Sung  Jin; Kim,Sung  Soon; Rhee,Jee  Eun

doi:10.3892/or.2013.2281

Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16

Authors:
- Ja Woon Yi
- Mi Jang
- Sung Jin Kim
- Sung Soon Kim
- Jee Eun Rhee
View Affiliations

Affiliations: Division of AIDS, Center for Immunology and Pathology, Korea National Institute of Health, Seoul, Republic of Korea
Published online on: February 7, 2013 https://doi.org/10.3892/or.2013.2281
Pages: 1617-1622

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The degradation of p53 by high-risk human papillomavirus (HR-HPV) E6 proteins is recognized as necessary for the immortalization of mammary epithelial cells and the progression of cancer. The HR-HPV type 16 E6 proteins exhibit numerous variants associated with different risk factors for the development of cervical cancer. Two variants of E6 proteins, D25E and L83V, are common in cervical carcinomas among Asian and European populations. In the present study, we compared the effect of two E6 variants on p53 degradation by a prototype E6 protein. We demonstrate that both the D25E and L83V variants downregulate p53 through a ubiquitin-proteasome pathway, and that the effect is very similar to that of the prototype E6 protein. The reduction in the p53 protein levels was induced through the ubiquitin-proteasome pathway via interaction with E6 proteins. The expression of p21 CIP1/WAF1, a downstream molecule of p53, was similarly reduced in both prototype and variant E6 protein-expressing cell lines, leading to aberrant G1/S cell cycle arrest. These results suggest that the natural variants, E6 D25E and L83V, similar to the prototype E6 protein, contribute to tumorigenesis by degrading p53.

View Figures

View References

1	Bosch FX, Manos MM, Muñoz N, et al: Prevalence of human papillomavirus DNA in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 87:796–802. 1995. View Article : Google Scholar
2	Liu Y, Chen JJ, Gao Q, et al: Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol. 73:7297–7307. 1999.PubMed/NCBI
3	Lehoux M, D’Abramo CM and Archambault J: Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics. 12:268–280. 2009. View Article : Google Scholar : PubMed/NCBI
4	Moody CA and Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 10:550–560. 2010. View Article : Google Scholar : PubMed/NCBI
5	Huibregtse JM, Scheffner M and Howley PM: A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10:4129–4135. 1991.PubMed/NCBI
6	Huertas-Salgado A, Martín-Gámez DC, Moreno P, et al: E6 molecular variants of human papillomavirus (HPV) type 16: an updated and unified criterion for clustering and nomenclature. Virology. 410:201–215. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ellis JR, Etherington I, Galloway D, et al: Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16. Lancet. 34:1069–1070. 1997. View Article : Google Scholar : PubMed/NCBI
8	Zehbe J, Mytilineos I, Wikstrom R, et al: Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol. 64:538–542. 2003. View Article : Google Scholar : PubMed/NCBI
9	Andersson S, Alemi M, Rylander E, et al: Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesions. Br J Cancer. 83:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
10	Zehbe I, Wilander E, Delius H, et al: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58:829–833. 1998.PubMed/NCBI
11	Stoppler MC, Ching K, Stoppler H, et al: Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol. 70:6987–6993. 1996.PubMed/NCBI
12	Chakrabarti O, Veeraraghavalu K, Tergaonkar V, et al: Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol. 78:5934–5945. 2004. View Article : Google Scholar : PubMed/NCBI
13	Cai HB, Chen CC and Ding XH: Human papillomavirus type 16 E6 gene variations in Chinese population. Eur J Surg Oncol. 36:160–163. 2010. View Article : Google Scholar : PubMed/NCBI
14	Matsumoto K, Yoshikawa H, Nakagawa S, et al: Enhanced oncogenicity of human papillomvairus type 16 (HPV16) variants in Japanese population. Cancer Lett. 56:159–165. 2000. View Article : Google Scholar
15	Kang S, Jeon YT, Kim JW, et al: Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical tissues of Korean women. Int J Gynecol Cancer. 15:107–112. 2005. View Article : Google Scholar : PubMed/NCBI
16	Jang M, Rhee JE, Jang DH and Kim SS: Gene expression profiles are altered in human papillomavirus-16 E6 D25E-expressing cell lines. Virol J. 8:4532011. View Article : Google Scholar : PubMed/NCBI
17	Thomas M, Pim D and Banks L: The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 18:7690–7700. 1999. View Article : Google Scholar : PubMed/NCBI
18	Kessis TD, Slebos RJ, Nelson WG, et al: Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA. 90:3988–3992. 1993. View Article : Google Scholar : PubMed/NCBI
19	Bernard HU, Calleja-Macias IE and Dunn ST: Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer. 118:1071–1076. 2006. View Article : Google Scholar : PubMed/NCBI
20	Hildesheim A and Wang SS: Host and viral genetics and risk of cervical cancer: a review. Virus Res. 89:229–240. 2002. View Article : Google Scholar : PubMed/NCBI
21	Zehbe I, Voglino G, Delius H, et al: Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet. 352:1441–1442. 1998. View Article : Google Scholar : PubMed/NCBI
22	Kämmer C, Tommasino M, Syrjänen S, et al: Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br J Cancer. 86:269–273. 2002.PubMed/NCBI
23	Grodzki M, Besson G, Clavel C, et al: Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomarkers Prev. 15:820–822. 2006. View Article : Google Scholar : PubMed/NCBI
24	McLaughlin-Drubin ME and Munger K: Oncogenic activities of human papillomaviruses. Virus Res. 143:195–208. 2009. View Article : Google Scholar : PubMed/NCBI
25	Howie HL, Katzenellenbogen RA and Galloway DA: Papillomavirus E6 proteins. Virology. 384:324–334. 2009. View Article : Google Scholar : PubMed/NCBI
26	Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
27	Rowland BD and Peeper DS: KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 6:11–23. 2006. View Article : Google Scholar : PubMed/NCBI
28	Munger K and Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res. 89:213–228. 2002. View Article : Google Scholar : PubMed/NCBI